

## 6.02 Pharmaceutical Modifications of Human Epididymis Protein 4 (HE4) has Antifibrotic and Anti-Inflammatory Effects on lung fibrosis

Paul Peppard<sup>1,2</sup>, Nazia Chaudhuri<sup>2</sup>, Koray Niels Potel<sup>2</sup>, Bettina Claudia Schock<sup>1</sup>

<sup>1</sup> Queen's University Belfast, Belfast, Antrim, UK.

<sup>2</sup> Ulster University, Derry, Londonderry, UK.

**Background:** HE4 (human epididymis protein 4), is fibrogenic and increased in fibrotic lung diseases, including systemic sclerosis with interstitial lung disease (SSc-ILD). Hypoxia and inflammation are typical features of SSc-ILD, and hypoxia induces HE4. Dapagliflozin, an inhibitor of sodium-dependent glucose co-transporter 2 (SGLT2) lowers HE4 in renal epithelial cells. We therefore investigated the effect of Dapagliflozin on hypoxia-induced HE4 and on fibrosis and inflammation in an in-vitro model of lung fibrosis.

**Methods:** Bronchial epithelial cells (16HBE14o-) cultured with Dapagliflozin (0-100µM) were exposed to normoxia (21%O<sub>2</sub>) or hypoxia (1%O<sub>2</sub>, 6h, 18h normoxia). Lung fibroblasts (CCD-11Lu) were cultured in 10% conditioned medium (CM) from 16HBE14o- cells. HE4, IL-8 and collagen deposition were determined by ELISA and Sirius RED staining.

**Results:** Dapagliflozin dose-dependently reduced hypoxia-induced HE4 in 16HBE14o- cells (Fig 1). In lung fibroblasts, the hypoxia-CM (Fig 2) showed significantly reduced expression of markers of inflammation (IL-8) and fibrosis (collagen deposition).



**Conclusions:** HE4 is an important mediator linking fibrosis and inflammation. Dapagliflozin inhibits HE4 and is anti-inflammatory and antifibrotic in a model of lung fibrosis.

**Keywords:** HE4, interstitial lung disease, lung fibrosis, pharmaceutical modification

**Disclosures:** PP was funded by the British Association for Lung Research (BALRSS23-02). The authors declare no conflict of interest.

**References:** (1) Huang X, *et al.* 2022 (doi: [10.1097/FJC.0000000000001268](https://doi.org/10.1097/FJC.0000000000001268))

**Fig 1.**



**Fig 2.**

